randomized_placebo_controlled_trial · 2006

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · Journal of Clinical Endocrinology and Metabolism

moderateDOI · 10.1210/jc.2005-1536PMID · 16352683Verified

View source

Plain-English summary

CJC-1295 produced sustained dose-related increases in growth hormone and IGF-1, but the study was small and did not test meaningful clinical outcomes.

Population

Healthy adults

Sample size

Intervention

Single or repeated subcutaneous CJC-1295 across ascending doses versus placebo

Outcomes measured

Growth hormone|IGF-1|Pharmacokinetics|Adverse events

Key findings

CJC-1295 caused sustained increases in growth hormone and IGF-1 and was relatively well tolerated in the short term.

Funding & disclosures

Commercial development involvement was present; detailed disclosures should be checked in the full article.

Limitations

Healthy volunteers, short follow-up and biomarker endpoints limit conclusions about therapeutic benefit and long-term safety.

Risk of bias

Moderate — randomized and blinded but small, early-phase and sponsor-linked.

Citation

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. https://doi.org/10.1210/jc.2005-1536

Linked peptides in the PeptiBrief database

→ CJC-1295